High Court Won't Hear Mylan IP Fight Over Benicar

The U.S. Supreme Court on Monday declined to take up Mylan Inc.'s argument that an appeals court incorrectly barred it from making generic versions of two hypertension drugs by applying a...

Already a subscriber? Click here to view full article